Sugi Predict

Sugi Predict / Compounds / Ammonia Solution, Strong

Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4608399

N.OC(Cc1ccccc1)(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.58
▸ CYP2C9 P11712 2/20 0.58
▸ CYP2C19 P33261 2/20 0.58
▸ FDPS P14324 1/20 0.52
▸ HIF1A Q16665 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ SLC6A2 P23975 1/20 0.48
▸ TAAR1 Q96RJ0 1/20 0.48
▸ TSHR P16473 1/20 0.46
▸ LMNA P02545 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ KCNA5 P22460 1/20 0.44
▸ TRPA1 O75762 1/20 0.43
▸ CALM1 P0DP23 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.42
▸ IDO1 P14902 2/20 0.40
▸ THRB P10828 1/20 0.40
▸ CES2 O00748 1/20 0.40
▸ CES1 P23141 1/20 0.40
▸ AKR1B1 P15121 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28607388 0.97 CYP1A2 (0.61) CYP1A2CYP2C9CYP2C19FDPSHIF1A
Ammonia Solution, Strong SCHEMBL8191774 0.85 CYP2C9 (0.50) CYP1A2CYP2C9CYP2C19FDPSHIF1A
SCHEMBL3273807 0.84 CYP1A2 (0.54) CYP1A2CYP2C9CYP2C19FDPSHIF1A
Ammonia Solution, Strong SCHEMBL29962813 0.83 CYP1A2 (0.58) CYP1A2CYP2C9CYP2C19FDPSHIF1A
SCHEMBL1825667 0.82 CYP1A2 (0.52) CYP1A2CYP2C9CYP2C19FDPSHIF1A
SCHEMBL925449 0.82 CYP1A2 (0.52) CYP1A2CYP2C9CYP2C19FDPSHIF1A
SCHEMBL2579939 0.82 CYP1A2 (0.52) CYP1A2CYP2C9CYP2C19FDPSHIF1A
SCHEMBL14935111 0.80 CYP2C19 (0.50) CYP1A2CYP2C9CYP2C19FDPSHIF1A
SCHEMBL10476772 0.80 CYP1A2 (0.61) CYP1A2CYP2C9CYP2C19FDPSHIF1A
SCHEMBL1421007 0.80 CYP1A2 (0.61) CYP1A2CYP2C9CYP2C19FDPSHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658846-B1 N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol for treating hepatitis virus infections UNITED THERAPEUTICS CORP (US) 2008-07-30 — — EP disclosed
US-20060264468-A1 Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections UNITED THERAPEUTICS CORPORATION 2006-11-23 — — US disclosed
US-7115632-B1 Sulfonyl aryl or heteroaryl hydroxamic acid compounds G. D. SEARLE & CO. (US) 2006-10-03 — — US disclosed
EP-1658846-A1 Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections G.D. SEARLE & CO. (US) 2006-05-24 — — EP disclosed
US-20050075374-A1 Sulfonyl aryl or heteroaryl hydroxamic acid compounds PHARMACIA CORPORATION 2005-04-07 — — US disclosed
US-6869951-B1 Method of changing conformation of a matrix metalloproteinase PHARMACIA CORPORATION (US) 2005-03-22 — — US disclosed
EP-0983267-B1 AMIDOAROMATIC RING SULFONAMIDE HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2005-01-26 — — EP disclosed
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 — — US disclosed
EP-0977745-B1 THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2004-12-01 — — EP disclosed
US-6794511-B2 AN ENZYME INHIBITORS OF METALLOPROTEASE; TREATING CONNECTIVE TISSUE DEGRADATION CAUSED BY INFLAMMATION OR TUMOR G. D. SEARLE 2004-09-21 — — US disclosed
EP-0973392-A1 SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 2000-01-26 — — EP disclosed
EP-0939629-A1 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO COMPANY (US) 1999-09-08 — — EP disclosed
WO-1998039315-A1 AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 — — WO disclosed
WO-1998039316-A1 N-HYDROXY 4-SULFONYL BUTANAMIDE COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 — — WO disclosed
WO-1998039313-A1 THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 — — WO disclosed
WO-1998038859-A1 SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 — — WO disclosed
WO-1998039326-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 — — WO disclosed
WO-1998039329-A1 AMIDOAROMATIC RING SULFONAMIDE HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 — — WO disclosed
WO-1998003166-A1 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO COMPANY (US) 1998-01-29 — — WO disclosed
US-4072756-A Tricyclo piperidino ketones and soporific compositions thereof SANDOZ LTD. (CH) 1978-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075374-A1 Sulfonyl aryl or heteroaryl hydroxamic acid compounds MMP1, MMP2, MMP3 CYP1A2 1309/4885CYP2C9 1143/4885CYP2C19 1165/4885
US-20060264468-A1 Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections IMPDH1, HAVCR2, DERA CYP1A2 1767/4885CYP2C9 2872/4885CYP2C19 2720/4885
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 CYP1A2 2019/4885CYP2C9 1868/4885CYP2C19 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.